Results 1 to 10 of about 46,962 (257)

Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12. [PDF]

PLoS ONE, 2012
Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of these signaling ...
Alison M McCaig, Emilio Cosimo, Michael T Leach, Alison M Michie   +3 more
doaj   +4 more sources

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia [PDF]

Journal of Clinical Oncology, 2008
Hagop M Kantarjian, Jorge Vela-Ojeda, Michael Deininger   +2 more
exaly   +2 more sources

Src Dependent Pancreatic Acinar Injury Can Be Initiated Independent of an Increase in Cytosolic Calcium [PDF]

, 2013
Several deleterious intra-acinar phenomena are simultaneously triggered on initiating acute pancreatitis. These culminate in acinar injury or inflammatory mediator generation in vitro and parenchymal damage in vivo. Supraphysiologic caerulein is one such
A Gnoni, A Pace, A Sharma, AJ Hietaranta, AK Saluja, AK Saluja, AS Gukovskaya, B Han, B Han, B Hofbauer, B Kruger, C Schafer, Catherine J. Baty, CH Kubisch, Chandra Durgampudi, Chathur Acharya, DN Criddle, Donna B. Stolz, EC Thrower, EM Parker, F Gorelick, F Mooren, F Nozu, G Lynch, H Weber, HK Baumgartner, I Gukovsky, I Gukovsky, I Samuel, JA Tapia, JA Williams, Jenny Karlsson, JV Gerasimenko, KA Muili, Krutika Patel, L Fischer, L Orlichenko, Lidiya Orlichenko, LJ Christopher, LJ Lombardo, LS Orlichenko, M Sendler, MS O'Konski, OA Mareninova, OH Petersen, Pawan Noel, PC Redondo, Rachel Cline, Ram Narayan Trivedi, RD Duan, RR Torgerson, RR Torgerson, S Kawabata, S Navina, Sarah Navina, SD Waterford, SG Weller, SJ Pandol, Sohail Z. Husain, Stuart E. Dryer, SZ Husain, SZ Husain, T Eley, T Grady, T Grady, V Sancho, Vijay P. Singh, Vivek Mishra, VP Singh, VP Singh, VP Singh, VP Singh, Y Tsunoda   +72 more
core   +12 more sources

Dasatinib targets c-Src kinase in cardiotoxicity

Toxicology Reports, 2023
Dasatinib is a multitargeted kinase inhibitor used for treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. Unfortunately, treatment of cancer patients with some kinase inhibitors has been associated with cardiotoxicity.
Manar Elmadani, Sami Raatikainen, Orvokki Mattila, Tarja Alakoski, Jarkko Piuhola, Pirjo Åström, Olli Tenhunen, Johanna Magga, Risto Kerkelä   +8 more
doaj   +1 more source

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia

Respiratory Medicine Case Reports, 2022
Dasatinib, an effective second-generation tyrosine kinase inhibitor, is used to treat breakpoint cluster region-Ableson-positive chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia.
Go Makimoto, Mahito Misawa, Yoshinobu Maeda, Katsuyuki Kiura   +3 more
doaj   +1 more source

Melatonin Attenuates Dasatinib-Aggravated Hypoxic Pulmonary Hypertension via Inhibiting Pulmonary Vascular Remodeling

Frontiers in Cardiovascular Medicine, 2022
Dasatinib treatment is approved as first-line therapy for chronic myeloid leukemia. However, pulmonary hypertension (PH) is a highly morbid and often fatal side-effect of dasatinib, characterized by progressive pulmonary vascular remodeling.
Rui Wang, Rui Wang, Jinjin Pan, Jinzhen Han, Miaomiao Gong, Liang Liu, Yunlong Zhang, Ying Liu, Dingyou Wang, Qing Tang, Na Wu, Lin Wang, Jinsong Yan, Hua Li, Yuhui Yuan   +14 more
doaj   +1 more source

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia

Haematologica, 2023
Dasatinib is a multi-kinase inhibitor with activity against the SRC kinase LCK, which plays a critical role in T-cell receptor signaling. Dasatinib, initially developed as an immunosuppressive agent, is by contrast, also noted to result in enhanced ...
Patrick Harrington, Richard Dillon, Deepti Radia, Philippe Rousselot, Donal P. McLornan, Mark Ong, Anna Green, Alessandro Verde, Farzana Hussain, Kavita Raj, Shahram Kordasti, Claire Harrison, Hugues de Lavallade   +12 more
doaj   +1 more source

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

Haematologica, 2013
Dasatinib is effective in most chronic phase chronic myeloid leukemia patients both in first-line therapy and following imatinib failure. While imatinib uptake into CD34+ cells is low compared to mononuclear cells, few data evaluate how well dasatinib ...
Devendra K. Hiwase, Verity A. Saunders, Eva Nievergall, Douglas D. Ross, Deborah L. White, Timothy P. Hughes   +5 more
doaj   +1 more source

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I [PDF]

, 2012
Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Badura, Susanne, Khateb, Mamduh, Mahajna, Jamal, Metodieva, Anna, Mian, Afsar Ali, Najajreh, Yousef, Ottmann, Oliver Gerhard, Ruimi, Nili, Ruthardt, Martin   +8 more
core   +1 more source

Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer. [PDF]

, 2014
Somatic mutations of the epidermal growth factor receptor often cause resistance to therapy with tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC). In this study, we aimed to identify partner drugs and pathways that can induce cell death in
Koeffler, H Phillip, Leong, Geraldine, Madan, Vikas, Mori, Seiichi, Sudo, Makoto, Yang, Henry   +5 more
core   +5 more sources